By Counterforce Health Team in Strimvelis (autologous CD34+ ADA-SCID gene therapy) —

How to Get Strimvelis Gene Therapy Covered by Blue Cross Blue Shield in Ohio: Complete Appeal Guide with Forms and Timelines

Answer Box: Getting Strimvelis Covered in Ohio

Strimvelis (ADA-SCID gene therapy) requires prior authorization from Blue Cross Blue Shield in Ohio, with appeals following a structured timeline: internal review (30 days), second-level appeal if needed, then external review through Ohio's Independent Review Organization (180-day deadline from final denial). Success depends on documenting severe ADA enzyme deficiency, failed standard therapies (PEG-ADA, HSCT ineligibility), and medical necessity for this Milan-only treatment. Start by calling BCBS member services for PA forms, then prepare comprehensive clinical documentation including genetic testing, enzyme assays, and treatment failure records.

First step today: Call Blue Cross Blue Shield Ohio at 1-800-676-BLUE (2583) to request prior authorization forms and confirm your plan's gene therapy coverage policy.

Table of Contents

  1. Read the Denial: Understanding BCBS Denial Codes
  2. Fixable Causes: Common Issues and Quick Fixes
  3. First-Level Appeal: Building Your Case
  4. Peer-to-Peer Review: Direct Physician Discussion
  5. Second-Level and External Review in Ohio
  6. Appeal Letter Templates and Scripts
  7. Tracking and Escalation Options
  8. Strengthening Your Medical Necessity Case
  9. If Appeals Fail: Alternative Options
  10. FAQ: Common Questions

Coverage at a Glance: Strimvelis and BCBS Ohio

Requirement What It Means Where to Find It Source
Prior Authorization Required for all gene therapies BCBS member portal or call 1-800-676-2583 BCBS Ohio
Formulary Status Likely non-formulary/specialty tier Plan formulary document Member handbook
Site of Care Only available at SR-TIGET, Milan, Italy Treatment location restriction EMA approval documentation
Diagnosis Requirements Confirmed ADA-SCID with enzyme deficiency Genetic testing, enzyme assays Clinical documentation
Appeals Deadline 180 days from final internal denial Ohio external review statute Ohio Dept of Insurance

Read the Denial: Understanding BCBS Denial Codes

When Blue Cross Blue Shield denies Strimvelis coverage, the denial letter will contain specific reason codes. Common denial reasons include:

Medical Necessity Denials:

  • "Experimental/investigational" - Despite EMA approval since 2016
  • "Not FDA approved" - U.S. regulatory status
  • "Lacks clinical evidence" - Insufficient documentation

Coverage Exclusions:

  • "Out-of-network provider" - SR-TIGET Milan location
  • "International treatment exclusion" - Travel/location restrictions
  • "No contracted facility" - Network limitations

Administrative Issues:

  • "Incomplete prior authorization" - Missing documentation
  • "Step therapy not completed" - PEG-ADA or HSCT requirements
  • "Benefit not covered" - Plan-specific exclusions
Tip: Save the original denial letter and note the exact appeal deadline. Ohio law gives you 180 days from the final internal denial to request external review.

Fixable Causes: Common Issues and Quick Fixes

Many Strimvelis denials can be overturned by addressing documentation gaps:

Missing Clinical Documentation

Fix: Submit complete ADA enzyme testing showing <1-3% normal activity, genetic confirmation of biallelic ADA mutations, and comprehensive treatment history.

Incomplete Step Therapy Documentation

Fix: Provide detailed records of PEG-ADA trials (doses, duration, response), HSCT evaluation (donor search results, contraindications), and disease progression despite standard care.

International Treatment Concerns

Fix: Include travel plan, SR-TIGET treatment protocol, cost breakdown, and medical necessity letter explaining why no U.S. alternative exists.

Coding Issues

Fix: Ensure proper ICD-10 codes (D81.3 for ADA deficiency) and work with SR-TIGET for appropriate procedure codes.

First-Level Appeal: Building Your Case

Required Documentation Checklist

  • Complete denial letter and member ID
  • Genetic testing results confirming ADA-SCID
  • Enzyme assays showing severe ADA deficiency
  • Treatment failure documentation (PEG-ADA records)
  • HSCT ineligibility assessment
  • Medical necessity letter from immunologist
  • EMA approval documentation and safety data
  • SR-TIGET treatment protocol and cost estimate

Medical Necessity Letter Components

Your physician's letter should address:

  1. Diagnosis confirmation: ADA-SCID with specific enzyme levels and genetic mutations
  2. Treatment failures: Detailed PEG-ADA trial history, HSCT contraindications
  3. Disease progression: Current immune status, infection history, quality of life impact
  4. Clinical rationale: Why Strimvelis is medically necessary and appropriate
  5. Literature support: Peer-reviewed studies, EMA approval basis, long-term outcomes
  6. Urgency factors: Risk of serious infection or death without treatment

Peer-to-Peer Review: Direct Physician Discussion

Request a peer-to-peer review when clinical complexity requires direct physician discussion.

Scheduling the Call

  • Contact BCBS medical director through member services
  • Provide 48-72 hours advance notice
  • Ensure your immunologist is available for the scheduled time

Preparation Checklist

  • Patient's complete medical history organized chronologically
  • Key lab values and genetic testing results
  • Treatment timeline with specific dates and outcomes
  • Literature references supporting Strimvelis efficacy
  • Questions about BCBS policy interpretation

Key Talking Points

  1. Severity: Emphasize life-threatening nature of ADA-SCID
  2. Standard care failure: Specific PEG-ADA doses, duration, lack of response
  3. HSCT limitations: Donor availability, patient-specific contraindications
  4. Strimvelis evidence: EMA approval, published outcomes, patient registry data
  5. Urgency: Risk of serious infection or death with delayed treatment

Second-Level and External Review in Ohio

Ohio External Review Process

If internal appeals fail, Ohio residents can request binding external review through an Independent Review Organization (IRO).

Stage Timeline Process
Internal Appeal Level 1 30 days standard, 72 hours expedited Submit via BCBS portal with complete documentation
Internal Appeal Level 2 30 days standard, 72 hours expedited Required before external review eligibility
External Review Request 180 days from final denial File with BCBS, forwarded to Ohio DOI
IRO Decision 30 days standard, 72 hours expedited Binding decision by medical experts

Filing External Review

  1. Submit written request to Blue Cross Blue Shield within 180 days
  2. Include all documentation: denial letters, medical records, new evidence
  3. Request expedited review if delay would seriously jeopardize health
  4. Contact Ohio DOI at 1-800-686-1526 with questions

The external review is free and the IRO decision is binding on Blue Cross Blue Shield.

Appeal Letter Templates and Scripts

Patient Phone Script for BCBS

"Hello, I'm calling about a denied prior authorization for Strimvelis gene therapy for my [relationship] with ADA-SCID. The denial reference number is [X]. I'd like to:

  1. Request the specific medical policy used for this denial
  2. Start the internal appeal process
  3. Request expedited review due to the life-threatening nature of this condition
  4. Get the direct fax number for submitting appeal documentation"

Medical Necessity Letter Template

Opening: "I am writing to appeal the denial of Strimvelis (autologous CD34+ gene therapy) for [patient name], a [age]-year-old with severe ADA-SCID."

Diagnosis section: "Laboratory confirmation shows ADA enzyme activity of [X]% of normal (reference range: [Y]). Genetic testing confirms biallelic mutations in the ADA gene: [specific mutations]."

Treatment history: "Despite [duration] of PEG-ADA therapy at [dose/frequency], the patient continues to experience [specific clinical problems]. HSCT is not an option due to [specific contraindications]."

Medical necessity: "Strimvelis represents the only curative option for this patient, with EMA approval based on [cite specific studies]. Without treatment, the prognosis is [specific timeline/outcomes]."

Tracking and Escalation Options

Appeal Tracking Log

Date Action Taken Contact Person Reference Number Follow-up Date
Initial denial received
Level 1 appeal submitted
Peer-to-peer requested
External review filed

When to Contact Ohio Department of Insurance

Contact ODI Consumer Services at 1-800-686-1526 if:

  • BCBS fails to respond within required timeframes
  • You believe BCBS violated Ohio insurance law
  • You need help understanding your appeal rights
  • BCBS incorrectly claims external review isn't available

Strengthening Your Medical Necessity Case

Evidence-Based Arguments

Clinical Guidelines:

  • Reference EMA approval and post-marketing surveillance data
  • Cite peer-reviewed studies showing Strimvelis efficacy
  • Include international treatment guidelines for ADA-SCID

Patient-Specific Factors:

  • Document specific contraindications to alternative treatments
  • Show progressive immune deterioration despite current therapy
  • Emphasize quality of life impacts and functional limitations

Economic Arguments:

  • Compare lifetime costs of supportive care vs. one-time curative treatment
  • Include indirect costs (hospitalizations, family impact, lost productivity)

From Our Advocates

"In our experience helping families navigate gene therapy appeals, the most successful cases combine three elements: comprehensive documentation of treatment failures, clear explanation of why the patient isn't a candidate for standard alternatives, and specific citations to the medical literature supporting the therapy's efficacy. While every case is unique and outcomes aren't guaranteed, thorough preparation significantly improves approval chances."

If Appeals Fail: Alternative Options

Manufacturer Support Programs

  • Contact Orchard Therapeutics patient support team
  • Explore compassionate use or expanded access programs
  • Investigate clinical trial opportunities

External Funding Sources

  • National Organization for Rare Disorders (NORD) grants
  • Patient advocate foundations
  • Crowdfunding platforms for medical expenses

Consider consulting with healthcare attorneys specializing in insurance coverage, particularly for cases involving:

  • ERISA-governed employer plans
  • Potential insurance bad faith claims
  • State insurance law violations

FAQ: Common Questions

Q: How long does Blue Cross Blue Shield prior authorization take in Ohio? A: Standard PA reviews take up to 30 days, but expedited reviews for urgent cases are completed within 72 hours. Request expedited review for ADA-SCID due to the life-threatening nature of the condition.

Q: What if Strimvelis is not on my formulary? A: Non-formulary drugs can still be covered through medical exception processes. Submit comprehensive documentation showing medical necessity and lack of formulary alternatives.

Q: Can I appeal if I've been denied coverage for international treatment before? A: Yes, each denial can be appealed separately. Previous denials don't prevent new appeals if you have additional clinical evidence or your condition has worsened.

Q: Does step therapy apply if I tried treatments in another state? A: Treatment failures from other locations typically satisfy step therapy requirements. Provide complete documentation from all treating physicians.

Q: What happens if the external review also denies coverage? A: External review decisions are binding on the insurer, but you may have additional legal remedies depending on your plan type and specific circumstances.

Q: How much does Strimvelis cost and are there payment assistance programs? A: The list price is approximately €594,000 (about $650,000 USD). Contact Orchard Therapeutics for information about patient assistance programs and payment options.

When navigating complex gene therapy approvals, having expert support can make a significant difference in your appeal's success. Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals by analyzing denial letters, payer policies, and clinical notes to craft point-by-point rebuttals aligned with each plan's specific requirements. Their platform helps patients, clinicians, and specialty pharmacies streamline the appeals process with payer-specific workflows and comprehensive documentation support.

For additional assistance with your Blue Cross Blue Shield appeal in Ohio, consider working with experienced advocates who understand both the clinical complexity of ADA-SCID and the specific requirements of Ohio insurance law. Counterforce Health can help ensure your appeal includes all necessary clinical evidence, proper citations, and compelling arguments tailored to your specific payer and situation.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on your specific plan terms and clinical circumstances. Always consult with your healthcare providers and insurance company for guidance specific to your situation. For complex appeals, consider working with qualified patient advocates or healthcare attorneys.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.